Company profile: Deciphera Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of kinase inhibitor–based cancer medicines leveraging a proprietary switch-control platform. Commercializes Ripretinib (QINLOCK) for advanced gastrointestinal stromal tumor after treatment with three or more kinase inhibitors, and develops a pipeline including Vimseltinib (CSF1R) for TGCT, DCC-3116 (ULK1/2) for cancers with RAS/RAF mutations, DCC-3084 (pan-RAF), and DCC-3009 (next‑gen KIT).
Products and services
- Ripretinib (QINLOCK): A kinase inhibitor used to treat advanced gastrointestinal stromal tumor (GIST) in patients previously treated with three or more kinase inhibitors
- Vimseltinib: An oral tyrosine kinase inhibitor targeting CSF1R, engineered to treat tenosynovial giant cell tumor (TGCT) and currently progressing through clinical trials
- DCC-3116: An investigational inhibitor targeting ULK1/2 kinases to inhibit autophagy, intended to treat cancers with RAS/RAF mutations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Deciphera Pharmaceuticals
Progenics Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Progenics Pharmaceuticals company profile →
Actuate Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics and clinical research focused on elraglusib for high-impact cancers and neurodegenerative diseases, including adult and pediatric injection and oral tablet formulations for advanced, refractory solid and hematological cancers (e.g., pancreatic, metastatic melanoma, colorectal), combination regimens with chemotherapy, ongoing trials to assess efficacy and safety, and partnerships with academic and scientific organizations
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actuate Therapeutics company profile →
ElsaLys Biotech
HQ: France
Website
- Description: Provider of therapeutic monoclonal antibody development, based in Lyon and Illkirch Graffenstaden, France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ElsaLys Biotech company profile →
Diatech Pharmacogenetics
HQ: Italy
Website
- Description: Provider of pharmacogenetics tests and precision medicine diagnostic solutions: Real Time PCR for variants of clinical interest in solid tumors and infectious diseases; Next Generation Sequencing equipment, libraries, and bioinformatics for SNPs, In/Del, CNV, and gene fusions in solid tumors; Pyrosequencing and fragment analysis for somatic or germline variants; and oncology equipment, kits, and software for analysis using MassArray technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diatech Pharmacogenetics company profile →
Umoja Biopharma
HQ: United States
Website
- Description: Provider of next-generation immunotherapies intended to combat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Umoja Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Deciphera Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Deciphera Pharmaceuticals
2.2 - Growth funds investing in similar companies to Deciphera Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Deciphera Pharmaceuticals
4.2 - Public trading comparable groups for Deciphera Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →